IL6 and non-small cell lung carcinoma: SBAs also bifurcate outcomes in NSCLC, FXR drives metastasis by transactivating IL-6ST/IL-6 and activates JAK2/STAT3, with higher FXR tumors showing worse prognosis and preclinical sensitivity to FXR inhibition [133, 197].